Take the smallest amount that you think would not create a reaction
In essence, the biosimilar market didnt start in the US as the first biosimilar was introduced in 2015-2016 timeframe
168 SeriB.Garcia-VerdugoJ
[4] Conditions that match a drugs FDA approval generally qualify, whether youre using these major GLP-1 brands or similar: Ozempic/Mounjaro: type 2 diabetes [5] Wegovy/Zepbound: obesity (BMI 30) [6] Wegovy/Zepbound: overweight with at least one weight-related condition (BMI 27 to under 30 plus hypertension, high cholesterol, sleep apnea, cardiovascular disease, or type 2 diabetes) [7] Zepbound: obstructive sleep apnea [8] Wegovy: metabolic-associated steatohepatitis (MASH) [9] Off-label conditions can count too when your clinician documents a real diagnosis such as prediabetes, binge eating disorder, or PCOS
Every patients body, health history, and goals are different, which is why our approach is personalized and medically supervised
Rates of hypoglycemia were not increased with berobenatide, according to Lingvay
